First-line Durvalumab Plus Tremelimumab Treatment for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice

Durvalumab plus tremelimumab combination therapy (STRIDE regimen) is a new first-line option for unresectable hepatocellular carcinoma (uHCC), but little real-world data is available to determine which patients are most likely to respond.